<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Latanoprost</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00654</strong>&#160; (APRD01065)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Latanoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.</p>
<p>It is also known by the brand name of Xalatan manufactured by Pfizer.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00654/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00654/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00654.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00654.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00654.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00654.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00654.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00654">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Latanoprost</td><td>French/German/Spanish</td><td>INN</td></tr><tr><td>Latanoprostum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Arulatan</td><td>Dr. Gerhard Mann</td></tr><tr><td>Gaap</td><td>Sophia</td></tr><tr><td>Gaap Ofteno</td><td>Sophia</td></tr><tr><td>Gaax</td><td>Chile</td></tr><tr><td>Glaucogesic</td><td>Atlas</td></tr><tr><td>Glaumax</td><td>Kevelt</td></tr><tr><td>Glauprost</td><td>Arrow</td></tr><tr><td>Hysite</td><td>Pfizer</td></tr><tr><td>Iopize</td><td>SIFI</td></tr><tr><td>Ioprost</td><td>FDC</td></tr><tr><td>Ioptame</td><td>Cadila</td></tr><tr><td>Klonaprost</td><td>Klonal</td></tr><tr><td>Lanoprost</td><td>Synpac-Kingdom</td></tr><tr><td>Lanotan</td><td>Kuk Je</td></tr><tr><td>Laprost</td><td>Oftalmi</td></tr><tr><td>Latacris</td><td>Sun-Farm</td></tr><tr><td>Latalux</td><td>Jelfa</td></tr><tr><td>Latan-Ophtal</td><td>Winzer</td></tr><tr><td>Lataneau</td><td>Alapis Pharma</td></tr><tr><td>Xalatan</td><td>Pfizer</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Arucom</td><td>Latanoprost and Timolol</td></tr><tr><td>Co-Latanoprost </td><td>Latanoprost and Timolol</td></tr><tr><td>Gaax T</td><td>Latanoprost and Timolol</td></tr><tr><td>Glaucogesic T</td><td>Latanoprost and Timolol</td></tr><tr><td>Glaucostat T</td><td>Latanoprost and Timolol</td></tr><tr><td>Laprost Plus </td><td>Latanoprost and Timolol</td></tr><tr><td>Xalacom</td><td>Latanoprost and Timolol</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>130209-82-4</td></tr><tr><th>Weight</th><td>Average: 432.5928<br>Monoisotopic: 432.28757439</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>40</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>GGXICVAJURFBLW-CEYXHVGTSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Eicosanoids</td></tr><tr><th>Subclass</th><td>Prostaglandins and related compounds</td></tr><tr><th>Direct parent</th><td>Prostaglandins and related compounds</td></tr><tr><th>Alternative parents</th><td>Carbocyclic Fatty Acids; Unsaturated Fatty Acids; Benzene and Substituted Derivatives; Cyclic Alcohols and Derivatives; Secondary Alcohols; Carboxylic Acid Esters; Ethers; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>benzene; cyclic alcohol; secondary alcohol; carboxylic acid ester; enolate; ether; carboxylic acid derivative; polyamine; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.</td></tr><tr><th>Pharmacodynamics</th><td>Latanoprost is an isopropyl ester prodrug which is inactive but which becomes active after hydrolysis to the acid from. Latanoprost opthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.</td></tr><tr><th>Mechanism of action</th><td>Latanoprost is a prostaglandin F2a analogue. Specifically, Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.</td></tr><tr><th>Absorption</th><td>Latanoprost is well absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form. Peak concentration is reached 2 hrs after topical administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1,2-dinor and 1,2,3,4-tetranor metabolites by fatty acid beta-oxidation.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>17 minutes</td></tr><tr><th>Clearance</th><td><ul>
	<li>7 mL/min/kg</li>
</ul></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include bloodshot eyes and eye irritation.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9474</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6512</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5337</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5728</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8684</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7124</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8805</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7819</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8835</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5947</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8845</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7724</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8985</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7236</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7393</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7405</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8324
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9379
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.6353
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          4.3748 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9071
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8763
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmacia and upjohn co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Assia Chemical Industries Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Ophthalmic</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00905">Bimatoprost</a></td><td>The concomitant use of bimatoprost and latanoprost may result in increased intraocular pressure. Consider avoiding this combination of therapy. Monitor for paradoxical increases in intraocular pressure during concomitant use. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>